AVICANNA INC (AVCN.CA) Stock News
TSX:AVCN - Toronto Stock Exchange - CA05368K1003 - Common Stock - Currency: CAD
AVCN.CA Latest News, Press Relases and Analysis
Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma
Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada...
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company
Cosmetic registration and delivery into Germany completed in preparation for the initial commercial Launch...
Avicanna Reports Q3 2024
9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 ...
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY...
Cannabis Flower Sales In Colombia And The Small Producer Protection Myth: Ex-Official Says Most Companies Qualify
Colombia's cannabis decree allows dry flower sales, but ex-official claims it won't just protect small producers—most companies may qualify.
Avicanna General Meeting
Annual General Meeting will be on July 10, 2024...
CBD's Toxicity Concerns: Could Europe Ban Cannabidiol In Cosmetics?
CBD could be deemed toxic for reproduction, which would then lead to its prohibition in cosmetic products across Europe.
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca
1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The...
Avicanna Announces Repayment of Debentures
TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage,...
Avicanna Announces Closing of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY...
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topicalcannabinoid composition and methods for treating...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
19th international market for Aureus branded products and 22nd market for all Avicanna products...
Avicanna Reports Q2 2024
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal...
Avicanna Announces Changes of Auditors
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July...
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company...
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna’s self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of...
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
Investors, advisors and analysts, will have the opportunity to attend in-person or participate online at VirtualInvestorConferences.com...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in...
Avicanna Announces Closing of Non-brokered Private Placement
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company...
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation...
Avicanna Reports Full Year 2023 Audited Financial Results
$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO,...
Avicanna anuncia el lanzamiento en Canadá de una formulación de su propiedad con un 10% de CBD (sin THC)
La formulación oral con un 10% de CBD (sin THC) se comercializa como RHO Phyto Micro Drop 100 en Canadá. RHO Phyto Micro Drop 100 está disponible...
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation
The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at...
Avicanna To Hold Full Year 2023 Earnings Conference Call
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, Chief Executive Officer, and also Phil Cardella, Chief Financial Officer where Mr. Azadian and Mr. Cardella will discuss the Company’s Full Year 2023 financial results.
Avicanna obtiene su primer registro de medicamento para indicación específica con Trunerox™
Aprobación emitida por la Autoridad Sanitaria de Colombia INVIMA para tratamiento adyuvante de convulsiones asociadas al Síndrome de Lennox-Gastaut (LGS) y...
Avicanna Hosts Symposium on Cannabinoid-based Medicine
Symposium seeks to bring Key Opinion Leaders and health care providers to explore cannabinoid-based R&D, medicine, and clinical adoption from the MaRS...
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
Research will assess the combination of Avicanna’s proprietary SEDDS technology in various drug delivery systems and dosage forms...
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet...